One of India's largest lyophilized-injection makers; also botulinum toxin, fertility drugs, APIs and CMO
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 120 | 164 | 259 | 338 | 523 | 591 | 619 | 654 |
| Borrowings | 126 | 62 | 64 | 334 | 333 | 336 | 369 | 405 |
| Other Liabilities | 152 | 157 | 188 | 179 | 227 | 232 | 271 | 273 |
| Total Liabilities | 408 | 392 | 521 | 861 | 1.1k | 1.2k | 1.3k | 1.3k |
| AssetsFixed Assets | 83 | 100 | 115 | 160 | 159 | 506 | 495 | 491 |
| CWIP | 31 | 13 | 41 | 170 | 307 | 22 | 24 | 22 |
| Investments | 0 | 0 | 0 | 1 | 2 | 3 | 3 | 3 |
| Other Assets | 294 | 279 | 365 | 531 | 625 | 639 | 747 | 826 |
| Total Assets | 408 | 392 | 521 | 861 | 1.1k | 1.2k | 1.3k | 1.3k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 5 | 47 | 87 | 106 | -27 | -7 | 123 | 44 |
| Cash from Investing | -13 | -43 | -7 | -95 | -191 | -102 | -72 | -31 |
| Cash from Financing | 8 | -4 | -79 | -6 | 234 | 82 | -37 | 32 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -8 | 7 | 75 | 19 | -214 | -116 | 52 | 13 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (43.5×) and current (56.5×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At -6.8% growth and a 44× exit, ₹355 only delivers your return if you pay ₹77. The price is currently baking in 23% growth.
EPS grows -6.8%/yr for 5 years, then fades to 6% over 2, exits at 44×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | -6.8% | 5.86 |
| FY28 | -6.8% | 5.46 |
| FY29 | -6.8% | 5.09 |
| FY30 | -6.8% | 4.75 |
| FY31 | -6.8% | 4.42 |
| FY32 | -0.4% ·fade | 4.41 |
| FY33 | 6.0% ·fade | 4.67 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.